Versant Venture Capital VI, L.P.

Insider Reports History

Location
San Francisco, CA
Signature
Versant Vantage II, LP By: Versant Vantage II GP, L.P. Its: General Partner By: Versant Vantage II GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Versant Venture Capital VI, L.P.:

Company Role Class Num Shares Value Price $ Report Date Ownership
LENZ Therapeutics, Inc. 10%+ Owner Common Stock 1,050,599 $49,392,125 $47.01 30 Sep 2025 Direct
Monte Rosa Therapeutics, Inc. 10%+ Owner Common Stock 4,079,469 $38,386,987 $9.41 28 Oct 2024 Direct
LENZ Therapeutics, Inc. 10%+ Owner Common Stock 764,127 $35,924,131 $47.01 30 Sep 2025 Indirect
Black Diamond Therapeutics, Inc. 10%+ Owner Common Stock 3,726,341 $23,551,220 $6.32 28 Aug 2024 Direct
Century Therapeutics, Inc. 10%+ Owner Common Stock 11,452,014 $17,063,501 $1.49 09 Aug 2022 Direct
Monte Rosa Therapeutics, Inc. 10%+ Owner Common Stock 1,573,453 $14,805,878 $9.41 29 Oct 2024 Indirect
Contineum Therapeutics, Inc. 10%+ Owner Class A Common Stock 375,535 $6,402,872 $17.05 09 Apr 2024 Direct
Black Diamond Therapeutics, Inc. 10%+ Owner Common Stock 822,140 $5,196,089 $6.32 28 Aug 2024 Indirect
Contineum Therapeutics, Inc. 10%+ Owner Class A Common Stock 148,312 $2,528,720 $17.05 09 Apr 2024 Indirect
Tempest Therapeutics, Inc. 10%+ Owner Common Stock 2,118,644 $2,331,568 $1.10 08 Aug 2024 Indirect
Century Therapeutics, Inc. 10%+ Owner Common Stock 714,095 $1,064,002 $1.49 09 Aug 2022 Indirect
Tempest Therapeutics, Inc. 10%+ Owner Common Stock 209,941 $231,040 $1.10 12 Aug 2024 Direct
LAVA Therapeutics NV 10%+ Owner Common Stock 0 $0 $1.40 19 Sep 2025 Direct
LAVA Therapeutics NV 10%+ Owner Common Stock 0 $0 $1.40 19 Sep 2025 Indirect
Contineum Therapeutics, Inc. 10%+ Owner Series B Preferred Stock 1,741,107 09 Apr 2024 Direct
Contineum Therapeutics, Inc. 10%+ Owner Series A-1 Preferred Stock 1,423,119 09 Apr 2024 Direct
Contineum Therapeutics, Inc. 10%+ Owner Series C Preferred Stock 710,494 09 Apr 2024 Indirect
Contineum Therapeutics, Inc. 10%+ Owner Series B Preferred Stock 434,725 09 Apr 2024 Indirect
Contineum Therapeutics, Inc. 10%+ Owner Series A Preferred Stock 9,252 09 Apr 2024 Indirect
Oyster Point Pharma, Inc. 10%+ Owner Common Stock 0 $11.20 03 Jan 2023 Direct
Oyster Point Pharma, Inc. 10%+ Owner Common Stock 0 $11.20 03 Jan 2023 Indirect

Insider Reports Filed by Versant Venture Capital VI, L.P.

Symbol Company Period Transactions Value $ Form Type Role Filing Time
LENZ LENZ Therapeutics, Inc. 30 Sep 2025 6 -$10,352,017 4 10%+ Owner 02 Oct 2025, 16:40
LVTX LAVA Therapeutics NV 19 Sep 2025 2 -$4,068,829 4 10%+ Owner 23 Sep 2025, 16:33
LENZ LENZ Therapeutics, Inc. 18 Sep 2025 6 -$5,714,356 4 10%+ Owner 22 Sep 2025, 16:23
LVTX LAVA Therapeutics NV 16 Sep 2025 6 -$2,502,261 4 10%+ Owner 18 Sep 2025, 18:49
LENZ LENZ Therapeutics, Inc. 22 Aug 2025 12 -$7,423,920 4 10%+ Owner 26 Aug 2025, 19:59
LENZ LENZ Therapeutics, Inc. 15 Aug 2025 4 -$10,255,244 4 10%+ Owner 19 Aug 2025, 16:51
LENZ LENZ Therapeutics, Inc. 10 Jul 2025 1 -$6,506,784 4 10%+ Owner 14 Jul 2025, 16:50
LENZ LENZ Therapeutics, Inc. 27 Jun 2025 1 -$6,093,000 4 10%+ Owner 01 Jul 2025, 18:16
LENZ LENZ Therapeutics, Inc. 18 Jun 2025 3 -$10,107,818 4 10%+ Owner 20 Jun 2025, 17:50
LENZ LENZ Therapeutics, Inc. 10 Jun 2025 1 -$10,150,000 4 10%+ Owner 12 Jun 2025, 16:37
LVTX LAVA Therapeutics NV 01 Jan 2025 0 $0 3 10%+ Owner 06 Feb 2025, 19:29
GLUE Monte Rosa Therapeutics, Inc. 28 Oct 2024 13 -$1,491,041 4 10%+ Owner 30 Oct 2024, 16:35
GLUE Monte Rosa Therapeutics, Inc. 20 Sep 2024 1 -$7,395,203 4 10%+ Owner 24 Sep 2024, 16:40
GLUE Monte Rosa Therapeutics, Inc. 11 Sep 2024 3 -$3,404,791 4 10%+ Owner 13 Sep 2024, 18:44
BDTX Black Diamond Therapeutics, Inc. 28 Aug 2024 1 -$1,400,556 4 10%+ Owner 30 Aug 2024, 16:16
TPST Tempest Therapeutics, Inc. 08 Aug 2024 2 -$967,033 4 10%+ Owner 12 Aug 2024, 20:33
CTNM Contineum Therapeutics, Inc. 09 Apr 2024 21 $0 4 10%+ Owner 11 Apr 2024, 18:10
CTNM Contineum Therapeutics, Inc. 04 Apr 2024 0 $0 3 10%+ Owner 04 Apr 2024, 21:22
LENZ LENZ Therapeutics, Inc. 21 Mar 2024 1 $0 4 10%+ Owner 25 Mar 2024, 16:30
/report/000089924323000677-versant-venture-capital-vi-l-p-2023-01-03 Oyster Point Pharma, Inc. 03 Jan 2023 4 $0 4 10%+ Owner 04 Jan 2023, 17:11
IPSC Century Therapeutics, Inc. 09 Aug 2022 2 -$7,166,610 4 10%+ Owner 11 Aug 2022, 16:55
TPST Tempest Therapeutics, Inc. 29 Apr 2022 0 $0 4 10%+ Owner 03 May 2022, 17:40
IPSC Century Therapeutics, Inc. 31 Jan 2022 1 $0 4 10%+ Owner 02 Feb 2022, 15:31
/report/000089924322001360-versant-venture-capital-vi-l-p-2022-01-05 Oyster Point Pharma, Inc. 05 Jan 2022 4 $0 4 10%+ Owner 07 Jan 2022, 15:20
IPSC Century Therapeutics, Inc. 23 Dec 2021 1 $0 4 10%+ Owner 28 Dec 2021, 15:46
/report/000089924321049594-versant-venture-capital-vi-l-p-2021-12-21 Oyster Point Pharma, Inc. 21 Dec 2021 4 $0 4 10%+ Owner 23 Dec 2021, 15:40
/report/000089924321040777-versant-venture-capital-vi-l-p-2021-10-18 Oyster Point Pharma, Inc. 18 Oct 2021 4 -$8,160,736 4 10%+ Owner 20 Oct 2021, 16:38
LENZ Graphite Bio, Inc. 29 Jun 2021 5 +$3,060,000 4 10%+ Owner 01 Jul 2021, 19:01
GLUE Monte Rosa Therapeutics, Inc. 28 Jun 2021 7 +$3,000,005 4 10%+ Owner 30 Jun 2021, 17:00
TPST Tempest Therapeutics, Inc. 25 Jun 2021 0 $0 3 10%+ Owner 06 Jul 2021, 18:26
LENZ Graphite Bio, Inc. 24 Jun 2021 0 $0 3 10%+ Owner 24 Jun 2021, 21:22
GLUE Monte Rosa Therapeutics, Inc. 23 Jun 2021 0 $0 3 10%+ Owner 23 Jun 2021, 20:29
IPSC Century Therapeutics, Inc. 22 Jun 2021 5 +$2,000,000 4 10%+ Owner 23 Jun 2021, 16:30
IPSC Century Therapeutics, Inc. 17 Jun 2021 0 $0 3 10%+ Owner 17 Jun 2021, 17:05
/report/000089924321019515-versant-venture-capital-vi-l-p-2021-05-12 Oyster Point Pharma, Inc. 12 May 2021 4 $0 4 10%+ Owner 14 May 2021, 16:45